LIGAND PHARMACEUTICALS INCORPORATED Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$22.05 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-29.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2024-02-29
- LIGAND PHARMACEUTICALS INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$22.05M, a 186.53% decline from fiscal 2022.
- LIGAND PHARMACEUTICALS INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $25.48M.
- LIGAND PHARMACEUTICALS INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was -$28.44M.
- LIGAND PHARMACEUTICALS INCORPORATED cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2020 was -$24.31M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|
| 2023-12-31 | -$22.05M 10-K · filed 2024-02-29 |
| 2022-12-31 | $25.48M 10-K · filed 2024-02-29 |
| 2021-12-31 | -$28.44M 10-K · filed 2024-02-29 |
| 2020-12-31 | -$24.31M 10-K · filed 2023-02-28 |
| 2019-12-31 | -$47.59M 10-K · filed 2022-02-28 |
| 2018-12-31 | $99.38M 10-K · filed 2021-02-24 |
| 2017-12-31 | $1.87M 10-K · filed 2020-02-27 |
| 2016-12-31 | -$78.68M 10-K · filed 2019-02-28 |